AHA to Sanofi U.S./Sanofi Genzyme Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs

AHA to Sanofi U.S./Sanofi Genzyme Re: Actions to Collect Data to Limit Distribution of Certain 340B Drugs to Hospitals and Health Systems

AHA expresses profound concern about actions Sanofi U.S./Sanofi Genzyme are taking to collect data intended to limit the distribution of certain 340B drugs to hospitals and health systems.

Related Resources

Action Alert
Member
New definition will have adverse effect on hospitals, especially those serving rural and vulnerable communities Please contact your senators and…
Special Bulletin
Public
House Democrats last night unveiled a new version of the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act – a $2.2 trillion COVID-19…
Letter/Comment
Public
AHA and other organizations representing the nation’s clinicians, hospitals, health systems and experts in health informatics and health information management…
Issue Landing Page
See below for the latest AHA members-only information to help hospital and health system leaders respond to the COVID-19 pandemic. For a comprehensive…
Issue Landing Page
See below for the latest information about what hospital and health system leaders should know in regards to supplies and personal protective equipment…
Advisory
Public
Sign In to Download the Regulatory Advisory: Inpatient PPS: The Final Rule for FY 2021   The Centers for Medicare & Medicaid Services (CMS) Sept…